Brief: Apyx Medical Receives FDA 510(K) Clearance For Use Of Renuvion
18/07/2022 14:08
July 18 (Reuters) - Apyx Medical Corp APYX.O :
* APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR
THE
USE OF RENUVION® TO IMPROVE APPEARANCE OF LAX (LOOSE) SKIN
* APYX MEDICAL CORP - EXPECT TO COMMENCE A LIMITED LAUNCH OF
RENUVION FOR THIS INDICATION BY END OF Q3 OF 2022
Source text for Eikon: ID:nBw5QFKYpa
Further company coverage: APYX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apyx Medical
See all newsBrief: Apyx Medical - Appoints Stavros Vizirgianakis As Executive Chairman Effective June 11, 2026
Brief: Apyx Medical Corporation Receives Expanded FDA 510(K) Clearance Adding Power Liposuction Capability To AYON Body Contouring System™
Apyx Medical Q1 revenue beats estimates, outlook raised
Preview: Weight-loss revolution sparks new appetite for aesthetics firms
Apyx Medical Q4 revenue beats on Surgical Aesthetics unit strength